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A B S T R A C T
Purpose: Convulsive Status Epilepticus (CSE) is a common neurological emergency with patients
presenting with prolonged epileptic activity. Sub-optimal management is coupled with high morbidity
and mortality. Continuous electroencephalogram (EEG) monitoring is considered essential by the
National Institute for Health and Care Excellence (NICE) in the management of Convulsive Refractory
Status Epilepticus (CRSE). The aim of this research was to determine current clinical practice in the
management of CRSE amongst adults in intensive care units (ICU) in the UK and establish if the use of a
standardised protocol requires re-enforcement within trusts.
Methods: 75 randomly selected UK NHS Trusts were contacted and asked to complete a questionnaire in
addition to providing their protocol for CRSE management in ICU.
Results: 55 (73%) trusts responded. While 31 (56% of responders) had a protocol available in ICU for early
stages of CSE, just 21 (38%) trusts had speciﬁc guidelines if CRSE occurred. Only 23 (42%) trusts involved
neurologists at any stage of management and just 18 (33%) have access to continuous EEG monitoring.
Conclusion: This study identiﬁes signiﬁcant inconsistency in the management of CSE in ICU’s across the
UK. A minority of ICU units have a protocol for CRSE or access to continuous EEG monitoring despite it
being considered fundamental for management and supported by NICE guidance.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Convulsive Status Epilepticus (CSE) is a life-threatening
neurological emergency with patients presenting with recurrent
seizure activity. Swift medical management is required to prevent
progression to Convulsive Refractory Status Epilepticus (CRSE) and
the associated high rates of mortality and morbidity. The current
International League against Epilepsy (ILEA) deﬁnition of CSE is a
‘condition in which epileptic activity persists for 30 min or more,
causing a wide spectrum of clinical symptoms, and with a highly
variable pathophysiological, anatomical and aetiological basis’.1
Thirty minutes has been acknowledged as the minimum duration
of time necessary for neuronal injury to occur.2,3* Corresponding author. Tel.: +44 07772815110.
E-mail addresses: mpatel59@doctors.org.uk (M. Patel),
Manny.Bagary@bsmhft.nhs.uk (M. Bagary).
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reAnimal models have shown that in CSE there is endocytosis of
inhibitory gamma-aminobutyric acid (GABAA), causing a reduction
of GABAA at the synaptic membrane. This leads to GABAA inactivity.
The movement of excitatory N-methyl-D-aspartic acid (NMDA)
and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) to the synaptic membrane during the initial stage of a
seizure leads to the development of further excitatory receptors
causing the progression from isolated seizures to CSE.4
In adults the frequent causes of CSE are cerebrovascular disease,
drugs and metabolic disturbances.5 Only 20% of adult patients have
had a prior neurological complaint. Acute brain injury usually leads
to new cases of CSE.6
CRSE has been labelled as CSE which is not controlled after
treatment with a minimum of two ﬁrst-line anti-epileptic drugs
(AED) or CSE persisting greater than 2 h without recovery despite
treatment.7 One multicentre study showed that 45% of cases
progressed to CRSE.8
The National Institute for Health and Care Excellence (NICE)
(2012) have provided a protocol for the management of CRSE andserved.
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anaesthetist and neurologist (2) continuous electroencephalogram
(EEG) monitoring is necessary for CRSE.9 This protocol replicates
the guidelines provided by NICE in 2004.
2. Convulsive Refractory Status Epilepticus management
The recommended treatment for terminating CSE is a benzodi-
azepine such as lorazepam or diazepam followed by phenytoin,
fospheytoin or phenobarbital.9 The continuation of seizure activity
with resistance to at least two AEDs is regarded as refractory,
requiring intensive care unit (ICU) input. Currently continuous EEG
monitoring in conjunction with an intravenous (IV) anaesthetic
infusion of midazolam, propofol or thiopental sodium is recom-
mended by NICE. The justiﬁcation for anaesthesia use in treatment
of CRSE is that brain damage is a consequence of continuous
electrographic seizure activity and the intention is to see a lack of
high frequency periods on the EEG known as burst suppression.10
Traditionally AEDs are withdrawn after burst suppression has
been achieved for at least 24 h11 although insufﬁcient data is
available to propose that burst suppression is necessary to manage
or avert seizure recurrence.13 Without continuous EEG monitoring
the treating clinician cannot assess the development of burst
suppression. This risks inappropriately excessive administration of
anaesthetic agents, or the continuation of electrical status
epilepticus with secondary deleterious injury to the brain.
As a tertiary referral centre we noted very different practices
within referring hospitals, particularly in the aspect of access to
EEG monitoring, drug treatment and the involvement of neurology
colleagues. We undertook a literature search but found no previous
publications comparing the management of CRSE in adults in
different acute trusts in the United Kingdom (UK).
2.1. Aims
We therefore undertook an audit with the following aims:
 Establish current treatment practice for CRSE in ICU across the
UK.
 Determine if NICE guidance for the management of CRSE is being
followed.
2.2. Methods
A list of all 162 acute National Health Service (NHS) Trusts in
the UK was identiﬁed and ordered alphabetically. A random
starting point was selected using a random number generator
corresponding to a trust on the list and every second trust
thereafter was included. We then performed a systematic random
selection of 75 trusts from this list. A brief questionnaire was then
sent to the trust’s patient advice and information services to be
forwarded to the ICU team under the agreement of the Freedom of
Information Act 2000. We asked respondents to answer ﬁve
speciﬁc questions:
1. Is a management plan in place for CSE?
2. Is a protocol for early CSE available in ICU?
3. Do you involve neurologists at any stage of management in
patients with CSE?
4. Is access to continuous EEG monitoring available?
5. Do you have a speciﬁc protocol if CRSE occurs?
We also asked each trust to send a copy of their protocol for
CRSE if they had one available.3. Results
The ﬂowchart (see Fig. 1) shows the results received from the
75 acute trusts selected.
Fifty ﬁve (73%) trusts responded to the participation responders
were either hospital managers, ICU nurses or ICU doctors. The
reason for no response was later sought after in the other 20 trusts.
Fifteen of these trusts did not reply on a second occasion. Four
trusts were updating their protocols and were not able to enclose
any information and one trust replied that they did not have the
information to send.
The results of each questions asked in the audit are shown
below.
3.1. Is a management plan in place for CSE?
Of the initial 55 respondents, 14 trusts had no management
plan in place. Eight of these stated that they did not hold this
information. Three trusts stated that they no longer treat or accept
patients in an acute setting, two were updating their protocols and
one trust did not follow recognised guidelines.
The initial CSE treatment in hospital was consistent across all
41 trusts with a management plan, stating that lorazepam 4 mg IV
with a repeat dose after 10 min would be administered.
Alternatively diazepam 10 mg would be used if indicated. All
trusts would then use phenytoin between 15 and 20 mg/kg,
however, the indicated time of use and dose of maintenance varied.
Sixteen trusts would infuse IV phenytoin 20–40 min after CSE had
begun and 13 trusts followed the NICE guidelines of between 0 and
60 min after CSE had been diagnosed. Eleven trusts did not state
how long the time interval would be before phenytoin was
administered with one trust simply stating on their protocol ‘if
seizures are not terminated phenytoin is used’. One trust would
use this AED between 60 and 90 min after CSE.
3.2. Is a protocol for early CSE available in ICU?
The second question focused on the protocol for early CSE
available in ICU. Thirty-one trusts had a protocol available of which
22 used their own guidelines but did not state who or when the
guidelines had been designed. Six trusts used the NICE guidelines
available in their ICU ofﬁce. Two trusts followed their nearby acute
trust protocol and one utilised the European Federation of
Neurology guidelines. For the ten trusts with no guidelines
available in ICU, seven stated that they would apply the NICE
guidelines, two would follow the advanced life support directives
and one trust stated they made use of the British National
Formulary.
3.3. Do you involve neurologists at any stage of management in
patients with CSE?
Next we assessed the neurological input into management
and 23 trusts involved a neurologist at some stage of their
treatment protocol. 13 followed the NICE guidelines which
simply states that patients ‘require care shared between the
anaesthetist and the neurologist from an early stage’. Therefore it
was not possible to determine when exactly the neurologist was
involved. The remaining showed marked variability for referral.
Three trusts would call the consultant neurologist as soon as
CRSE had begun. Two trusts seeked a neurology consultant’s
review for all patients who were admitted to ICU with one of these
trusts transferring the patient to a neurology unit as soon as the
patient reached CSE. The remaining four stated that either
neurologist input occurred after the ﬁrst onset of seizure, after
10 min of seizure activity, ‘early referral’ and ‘uncertain when to
Fig. 1. Results of the audit when asked about the ﬁve key questions.
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neurological input within their protocol and 11 of these did not
state who would assist the patient care and decision making. Three
trusts contacted the on-call anaesthetist, three would get help
from the ICU registrar or ‘senior’ and one trust were advised by the
on-call medical doctor.
3.4. Is access to continuous EEG monitoring available?
When asked about EEG monitoring, which is stated as
essential by NICE in the management protocol, 23 trusts did
not indicate if EEG was a part of their protocol or if they had
access to continuous EEG. Of the 18 trusts with access to EEG,
15 trusts would ﬁrst use the equipment as soon as the patient
was intubated and transferred to ICU. Two trusts would use the
EEG as soon as general anaesthesia was given and one trust as
soon as CRSE began.3.5. Do you have a speciﬁc protocol if CRSE occurs?
The ﬁnal question concentrated on the guidelines for CRSE. Only
21 trusts had any guidelines in place (see Fig. 2). 13 followed the
NICE guidelines of a triple option of either propofol (1–2 mg/kg
bolus, then 2–10 mg/kg/h), thiopental sodium (3–5 mg/kg bolus,
then 3–5 mg/kg/h) or midazolam (0.1–0.2 mg/kg bolus, then 0.05–
0.5 mg/kg/h). Four trusts employed the same option with no doses
speciﬁed. Thiopental sodium was the ﬁrst choice in four trusts with
three using a dose of 4 mg and the other not specifying a dose. One
trust utilised propofol 1–2 mg/kg and one stated using ‘general
anaesthesia’ with no speciﬁc AED mentioned.
Looking at when anaesthetic management would be ended, 14 of
the 21 trusts with guidelines for CRSE would continue treatment until
a primary endpoint of EEG activity suppression was seen. Five simply
replied that EEG would be used with no endpoint noted. Two trusts
continued anaesthesia 12–24 h after seizure activity had ended.
Fig. 2. The anaesthetic management of CRSE.
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The main strength of this study is that there is no previous
published audit that has compared the management of adult CRSE
amongst acute trusts in the UK. We have identiﬁed signiﬁcant
differences within the protocols which may cause delay in efﬁcient
treatment and put patients at risk of potential preventable harm.
Of the 55 respondents, only 21 trusts have guidelines for CRSE
management and 18 trusts use or have access to continuous EEG.
Similar results of variation in management of CRSE were also
shown in a European survey of epileptologists and critical care
neurologists.12
One limitation of this audit was the missing data from the non-
responding acute trusts. Twenty trusts did not respond and
feedback from these non-respondents on the questionnaire style
and layout may increase the response in any future audit.
Questionnaires may also not reﬂect front line clinical practice.
An additional drawback is that the questionnaire may not have
captured the management strategies that are not included in the
trust protocol.
Neurologists surprisingly may not be consulted in patient care
or are included very late in the management plan despite CSE being
a neurological emergency. A diagnostic problem is that as many as
half of all patients presenting to hospital with SE have been found
to not have epilepsy13 with non-epileptic seizures (NES) common-
ly misdiagnosed. Admitting neurologists have been able to
accurately predict such occurrences in 67% of cases14 enhancing
the argument for early neurologist input. The early use of EEG prior
to ITU transfer can also help differentiate NES, as alpha waves
between movement artefacts do not occur in CSE.
One major barrier to following NICE guidance on CRSE is limited
local resources. The European Society of Intensive Care Medicine
recommended continuous use of EEG for CRSE rather than
intermittent use.15 However, EEG monitoring may not be available
in many trusts due to a lack of neurophysiological services.
Similarly, a neurologist may not be involved because local
expertise is unavailable. The ideal solution, in our view, would
be for patients with CRSE to have early referral to a tertiary
neuroscience centre, especially for super refractory cases or when
the diagnosis is in doubt. Such centres can provide specialised
neuro-intensive care experience, continuous EEG monitoring,
specialist neurological advice and practical experience in manag-
ing CRSE. However with limited neurology ICU beds, other optionsinclude using a bispectral index score (BIS) to guide burst
suppression therapy or limited channel EEG with four channel
recordings, which has a 98% speciﬁcity for seizure detection.16
There are many unanswered questions in the management of
CRSE such as drug choice, drug dosage, time interval before
providing anaesthetic treatment and the ratio for burst suppres-
sion. Unfortunately, there is limited evidence to answer these
questions which may further promote inconsistency in manage-
ment practice. Therefore the established best practice recom-
mended by NICE ﬁnishes with the advice of continuous EEG
monitoring and access to specialist neurological advice.
This audit highlighted the variation of CRSE management in the
UK and we hope that this paper will stimulate local service
development and improve standards. There is a need to review the
management across all trusts in the UK and also internationally,
with standardised practice potentially providing a signiﬁcant step
in optimising patient care and reducing the mortality and long
term morbidity associated with CRSE.
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